A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Sponsor: Altor BioScience
A PHASE1/PHASE2 clinical study on Malignant Tumor of Renal Pelvis and Transitional Cell Carcinoma of Bladder, this trial is completed. The trial is conducted by Altor BioScience and has accumulated 10 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Jun 2024 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Sep 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Altor BioScience
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .